Key Takeaways LivaNova received FDA approval for aura6000 to treat moderate to severe OSA in adults.LIVN's p-HGNS therapy showed reduced apnea events and sustained benefits in the OSPREY trial.LIVN's device expands treatment options and supports future growth with next-gen system plans.LivaNova (LIVN) recently received premarket approval from the FDA for its aura6000 system to treat adults with moderate to severe Obstructive Sleep Apnea (OSA). The system uses proximal hypoglossal nerve stimulation (p-HGNS), ...